Financial Performance - The company's revenue for Q1 2025 reached ¥3,098,813,569.89, representing a 16.03% increase compared to ¥2,670,740,738.16 in the same period last year[6] - Net profit attributable to shareholders was ¥305,575,186.04, up 32.54% from ¥230,557,834.70 year-on-year[6] - The adjusted net profit attributable to shareholders was ¥349,441,031.17, reflecting a 3.14% increase from ¥338,816,299.13 in the previous year[6] - Total revenue for the period reached CNY 3,098,813,569.89, an increase of 15.9% compared to CNY 2,670,740,738.16 in the previous period[35] - Net profit for the period was CNY 279,654,565.09, representing a 29.5% increase from CNY 215,919,833.12 in the prior period[36] - The company reported a profit before tax of RMB 363,587,000, compared to RMB 268,619,000 in the previous year, an increase of 35.4%[42] - Total comprehensive income for the period reached RMB 389,670,737.53, compared to RMB 162,642,198.05 in the previous period, representing an increase of approximately 139.5%[37] Revenue Breakdown - Revenue from laboratory services was ¥1,857,202,616.77, a 15.74% increase from ¥1,604,576,678.01 year-on-year, with a gross margin of 45.54%[8] - Revenue from CMC (small molecule CDMO) services was ¥693,023,486.59, up 19.05% from ¥582,104,488.92, with a gross margin of 30.44%[8] - Revenue from clinical research services reached ¥447,320,929.08, a 14.25% increase from ¥391,531,326.06, with a gross margin of 11.76%[8] - Revenue from the top 20 global pharmaceutical companies was ¥455,746,000, a 29.05% increase, accounting for 14.71% of total revenue[9] Shareholder Metrics - Basic earnings per share increased by 33.54% to CNY 0.1736, reflecting the growth in net profit attributable to shareholders[14] - Diluted earnings per share rose by 33.51% to CNY 0.1733, also attributed to the increase in net profit[15] - The total number of common shareholders at the end of the reporting period was 79,841[20] - The company announced a profit distribution plan for the year 2024, which is expected to enhance shareholder value[28] Cash Flow and Assets - The company's cash flow from operating activities amounted to ¥852,829,144.27, a 14.38% increase compared to ¥745,630,586.78 in the same period last year[6] - Cash flow from investing activities resulted in a net outflow of RMB 1,212,095,238.52, worsening from a net outflow of RMB 467,094,044.67 in the previous period[40] - Cash flow from financing activities showed a net outflow of RMB 98,926,715.92, an improvement compared to a net outflow of RMB 1,512,600,594.24 last period[41] - The total current assets decreased from CNY 7,608,179,522.72 to CNY 7,384,443,685.17, representing a decline of approximately 2.95%[30] - Cash and cash equivalents decreased from CNY 1,689,916,082.15 to CNY 1,262,763,166.96, a reduction of about 25.3%[30] Expenses and Liabilities - Total operating costs amounted to CNY 2,713,717,115.43, up from CNY 2,439,362,705.75, reflecting a growth of 11.2%[35] - Research and development expenses grew by 30.56% to CNY 122,210,590.15, indicating a continued commitment to R&D investment[18] - Income tax expenses rose by 59.27% to CNY 83,932,205.84, corresponding to the increase in total profit[19] - The total liabilities decreased slightly to CNY 9,686,700,206.35 from CNY 9,704,526,037.38, a reduction of 0.2%[33] Other Financial Metrics - Other comprehensive income increased significantly by 1,370.30% to CNY 98,545,941.98, driven by foreign currency translation differences and cash flow hedging[18] - The company's total non-current assets increased to CNY 16,948,379,035.81 from CNY 16,319,218,798.51, marking a growth of 3.9%[31] - The equity attributable to the parent company increased to RMB 14,042,172 thousand from RMB 13,619,335 thousand, marking a growth of 3.1%[44] - The company's goodwill increased to RMB 2,947,429 thousand from RMB 2,760,736 thousand, reflecting a growth of 6.8%[43]
康龙化成(03759) - 2025 Q1 - 季度业绩